Protection against lipopolysaccharide-induced death by fluoroquinolones

被引:53
作者
Khan, AA
Slifer, TR
Araujo, FG
Suzuki, Y
Remington, JS
机构
[1] Palo Alto Med Res Fdn, Res Inst, Dept Immunol & Infect Dis, Palo Alto, CA 94301 USA
[2] Stanford Univ, Sch Med, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA
关键词
D O I
10.1128/AAC.44.11.3169-3173.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Because fluoroquinolones have an immunomodulatory effect on cytokine production by lipopolysaccharide (LPS)-treated human monocytes, we examined the effect of fluoroquinolones on the survival of mice injected with a lethal dose of LPS. Trovafloxacin (100 mg/kg), ciprofloxacin (250 mg/kg), and tosufloxacin (100 mg/kg) protected 75% (P = 0.0001), 25% (P = 0.002), and 50% (P = 0.002), respectively, of mice against death. The fluoroquinolones significantly reduced serum levels of interleukin-6 and tumor necrosis factor alpha in LPS-treated mice. The protective effects of fluoroquinolones in LPS-induced shock in mice may also occur in humans.
引用
收藏
页码:3169 / 3173
页数:5
相关论文
共 22 条
  • [1] Abraham E, 1998, LANCET, V351, P929
  • [2] ANDERSON BO, 1991, SURG GYNECOL OBSTET, V172, P415
  • [3] BAILLY S, 1991, CLIN EXP IMMUNOL, V85, P331
  • [4] TUMOR NECROSIS, CACHEXIA, SHOCK, AND INFLAMMATION - A COMMON MEDIATOR
    BEUTLER, B
    CERAMI, A
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1988, 57 : 505 - 518
  • [5] A 2ND LARGE CONTROLLED CLINICAL-STUDY OF E5, A MONOCLONAL-ANTIBODY TO ENDOTOXIN - RESULTS OF A PROSPECTIVE, MULTICENTER, RANDOMIZED, CONTROLLED TRIAL
    BONE, RC
    BALK, RA
    FEIN, AM
    PERL, TM
    WENZEL, RP
    REINES, HD
    QUENZER, RW
    IBERTI, TJ
    MACINTYRE, N
    SCHEIN, RMH
    TRENHOLME, G
    NIEDERMAN, M
    CHALFIN, D
    ABALOS, A
    OROPELLO, J
    EMPSON, P
    CAMINITII, S
    GREENMAN, R
    BOOTH, F
    PLOUFFE, J
    RUSSELL, J
    GIANAKOPOULOS, G
    IANNINI, P
    HINDES, R
    COBLENS, K
    KOHLER, R
    MARTIN, M
    BERNARD, G
    EDWARDS, J
    CRISLIP, M
    FILLER, S
    NASRAWAY, SA
    SIGEL, PK
    SOTTILE, FD
    MARTIN, DH
    DEBOISBLANC, BP
    CHANDRASEKAR, PH
    BROUGHTON, WA
    MIDDLETON, RM
    SEIBERT, AF
    EMMANUEL, G
    LIE, TH
    ANDERSON, CLV
    PANKEY, GA
    ANDERSON, P
    OLSEN, K
    SANPEDRO, GS
    GRAHAM, D
    GROSSMAN, J
    WELS, PB
    [J]. CRITICAL CARE MEDICINE, 1995, 23 (06) : 994 - 1006
  • [6] A CONTROLLED CLINICAL-TRIAL OF HIGH-DOSE METHYLPREDNISOLONE IN THE TREATMENT OF SEVERE SEPSIS AND SEPTIC SHOCK
    BONE, RC
    FISHER, CJ
    CLEMMER, TP
    SLOTMAN, GJ
    METZ, CA
    BALK, RA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (11) : 653 - 658
  • [7] INTERLEUKIN 1-INDUCED PATHO-PHYSIOLOGY - INDUCTION OF CYTOKINES, DEVELOPMENT OF HISTOPATHOLOGIC CHANGES, AND IMMUNOPHARMACOLOGIC INTERVENTION
    BUTLER, LD
    LAYMAN, NK
    CAIN, RL
    RIEDL, PE
    MOHLER, KM
    BOBBITT, JL
    BELAGAJIE, R
    SHARP, J
    BENDELE, AM
    [J]. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1989, 53 (03): : 400 - 421
  • [8] INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis
    Cohen, J
    Carlet, J
    [J]. CRITICAL CARE MEDICINE, 1996, 24 (09) : 1431 - 1440
  • [9] Sepsis and serum cytokine concentrations
    Damas, P
    Canivet, JL
    DeGroote, D
    Vrindts, Y
    Albert, A
    Franchimont, P
    Lamy, M
    [J]. CRITICAL CARE MEDICINE, 1997, 25 (03) : 405 - 412
  • [10] PLATELET-ACTIVATING-FACTOR RECEPTOR ANTAGONIST BN-52021 IN THE TREATMENT OF SEVERE SEPSIS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER CLINICAL-TRIAL
    DHAINAUT, JFA
    TENAILLON, A
    LETULZO, Y
    SCHLEMMER, B
    SOLET, JP
    WOLFF, M
    HOLZAPFEL, L
    ZENI, F
    DREYFUSS, D
    MIRA, JP
    DEVATHAIRE, F
    GUINOT, P
    [J]. CRITICAL CARE MEDICINE, 1994, 22 (11) : 1720 - 1728